Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia

Molecular Medicine Reports

Volumn 1, Issue 5, 2008, Pages 757-761

  Mattsson, Niklas ^a,e   Rüetschi, Ulla ^b   Pijnenburg, Yolande A L ^c   Blankenstein, Marinus A ^c   Podust, Vladimir N ^d   Li, Susann ^b   Fagerberg, Inger ^b   Rosengren, Lars ^a   Blennow, Kaj ^a   Zetterberg, Henrik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CIPHERGEN BIOSYSTEMS INC   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarkers; Dementia; FTD; Neurodegeneration; Neurofilament; Osteopontin; Proteomics

Indexed keywords

BIOLOGICAL MARKER; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; NEUROFILAMENT PROTEIN; OSTEOPONTIN; PANCREATIC RIBONUCLEASE; PEPTIDE;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CHROMATOGRAPHY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; LIGHT CHAIN; MALE; NERVE FIBER DEGENERATION; NEUROFILAMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PEPTIDE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

EID: 69449086402     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000025     Document Type: Article

References (33)

1. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J and Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51: 1546-1554, 1998. (Pubitemid 28565230)
2. Hodges JR and Patterson K: Non-fluent progressive aphasia and semantic dementia: a comparative neuropsychological study. J Int Neuropsychol Soc 2: 511-524, 1996.
3. Hodges JR, Patterson K, Oxbury S and Funnell E: Semantic dementia: progressive fluent aphasia with temporal lobe atrophy. Brain 115: 1783 - 1806, 1992.
4. Pasquier F, Lebert F, Lavenu I and Guillaume B: The clinical picture of frontotemporal dementia: Diagnosis and follow up. Dement Geriatr Cogn Disord 10 (Suppl 1): 10-14, 1999. (Pubitemid 29348608)
5. Josephs KA, Whitwell JL, Jack CR, Parisi JE and Dickson DW: Frontotemporal lobar degeneration without lobar atrophy. Arch Neurol 63: 1632-1638, 2006. (Pubitemid 44748808)
6. Davies RR, Kipps CM, Mitchell J, Kril JJ, Halliday GM and Hodges JR: Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol 63: 1627-1631, 2006. (Pubitemid 44748807)
7. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL III, Schneider JA, Grinberg LT, Halliday G, Duyckaerts C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, Trojanowski JQ, Mann DM; Consortium for Frontotemporal Lobar Degeneration: Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114: 5-22, 2007.
8. Broe M, Hodges JR, Schofield E, Shepherd C, Kril J and Halliday G: Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology 60: 1005-1011, 2003. (Pubitemid 36348937)
9. Broe M, Kril J and Halliday GM: Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain 127: 2214-2220, 2004. (Pubitemid 39382230)
10. Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K and Wallin A: Cytoskeleton proteins in CSF distinguish fronto-temporal dementia from AD. Neurology 54: 1960-1964, 2000.
11. Fukuyama R: An immunochemical study of GFAP (glial fibrillary acidic protein) expression in the mouse central nervous system supplemented with its analysis by protein chemistry. J Kyoto Pref Univ Med 96: 485-501, 1984.
12. Crols R, Saerens J, Noppe M and Lowenthal A: Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome. J Neurol 233: 157-160, 1986. (Pubitemid 16114595)
13. Rosengren LE, Wikkelso C and Hagberg L: A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods 51: 197-204, 1994. (Pubitemid 24110093)
14. Rüetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid Simonsen A, McGuire J, Karlsson M, Rymo L, Davies H, Minthon L and Blennow K: Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 196: 273-281, 2005. (Pubitemid 41607815)
15. Roberson ED, Hesse JH, Rose KD, Slama H, Johnson JK, Yaffe K, Forman MS, Miller CA, Trojanowski JQ, Kramer JH and Miller BL: Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology 65: 719-725, 2005. (Pubitemid 41285851)
16. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414, 1993.
17. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI and Wikkelso C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67: 2013-2018, 1996.
18. Mattsson N, Rüetschi U, Podust VN, Stridsberg M, Li S, Andersen O, Haghighi S, Blennow K and Zetterberg H: Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem. 103: 1932-1939, 2007.
19. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, Cudkowicz ME, Brown RH Jr and Bowser R: Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 95: 1461-1471, 2005. (Pubitemid 41779269)
20. Marcinkiewicz M: Expression of neuroendocrine secretory protein 7B2 mRNA in the mouse and rat pituitary gland. Neuroendocrinology 58: 86-93, 1993.
21. Marcinkiewicz M, Touraine P and Chretien M: Pan-neuronal mRNA expression of the secretory polypeptide 7B2. Neurosci Lett 177: 91-94, 1994. (Pubitemid 24269437)
22. Muller L and Lindberg I: The cell biology of the prohormone convertases PC1 and PC2. Prog Nucleic Acid Res Mol Biol 63: 69-108, 1999.
23. Chaudhuri B: The neuroendocrine protein 7B2 acts as a molecular chaperone in the in vitro folding of human insulin-like growth factor-1 secreted from yeast. Biochem Biophys Res Commun 211: 417-425, 1995.
24. Fisher LW, Torchia DA, Fohr B, Young MF and Fedarko NS: Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 280: 460-465, 2001. (Pubitemid 32912812)
25. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR and Steinman L: The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294: 1731-1735, 2001. (Pubitemid 33104847)
26. Teismann P and Schulz JB: Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318: 149-161, 2004. (Pubitemid 39362635)
27. Wung JK, Perry G, Kowalski A, Harris PL, Bishop GM, Trivedi MA, Johnson SC, Smith MA, Denhardt DT and Atwood CS: Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain. Curr Alzheimer Res 4: 67-72, 2007. (Pubitemid 46293885)
28. Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, Mueller JC, Liaw L, Gasser T and Nitsch C: Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis 25: 473-482, 2007. (Pubitemid 46304237)
29. Burdo TH, Wood MR ans Fox HS: Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol 81: 1504-1511, 2007.
30. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, Kapaki E, Vassilopoulos D and Waldemar G: A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24: 434-440, 2007. (Pubitemid 350175903)
31. Greenway MJ, Alexander MD, Ennis S, Traynor BJ, Corr B, Frost E, Green A and Hardiman O: A novel candidate region for ALS on chromosome 14q11.2. Neurology 63: 1936-1938, 2004.
32. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, Paterson V, Swingler R, Morrison KE, Green A, Acharya KR, Brown RH and Hardiman O: Loss-of-function ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 38: 411-413, 2006.
33. Crabtree B, Thiyagarajan N, Prior SH, Wilson P, Iyer S, Ferns T, Shapiro R, Brew K, Subramanian V and Acharya KR: Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis. Biochemistry 46: 11810-11818, 2007. (Pubitemid 47623749)